| Hyperglycaemia and Adverse Pregnancy Outcome (HAPO) Study: associations with maternal body mass index. | |
| | |
MedLine Citation:
|
PMID: 20089115 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: To determine whether higher maternal body mass index (BMI), independent of maternal glycaemia, is associated with adverse pregnancy outcomes. DESIGN: Observational cohort study. SETTING: Fifteen centres in nine countries. POPULATION: Eligible pregnant women. METHODS: A 75-g 2-hour oral glucose tolerance test (OGTT) was performed between 24 and 32 weeks of gestation in all participants. Maternal BMI was calculated from height and weight measured at the OGTT. Fetal adiposity was assessed using skinfold measurements and percentage of body fat was calculated. Associations between maternal BMI and pregnancy outcomes were assessed using multiple logistic regression analyses, with adjustment for potential confounders. MAIN OUTCOME MEASURES: Predefined primary outcomes were birthweight >90th percentile, primary caesarean section, clinical neonatal hypoglycaemia and cord serum C-peptide >90th percentile. Secondary outcomes included pre-eclampsia, preterm delivery (before 37 weeks) and percentage of body fat >90th percentile. RESULTS: Among 23 316 blinded participants, with control for maternal glycaemia and other potential confounders, higher maternal BMI was associated (odds ratio [95% confidence interval] for highest {> or =42.0 kg/m(2)} versus lowest {<22.6 kg/m(2)} BMI categories) with increased frequency of birthweight >90th percentile (3.52 [2.48-5.00]) and percentage of body fat >90th percentile (3.28 [2.28-4.71]), caesarean section (2.23 [1.66-2.99]), cord C-peptide >90th percentile (2.33 [1.58-3.43]) and pre-eclampsia (14.14 [9.44-21.17]). Preterm delivery was less frequent with higher BMI (0.48 [0.31-0.74]). Associations with fetal size tended to plateau in the highest maternal BMI categories. CONCLUSION: Higher maternal BMI, independent of maternal glycaemia, is strongly associated with increased frequency of pregnancy complications, in particular those related to excess fetal growth and adiposity and to pre-eclampsia. |
| | |
Authors:
|
|
Related Documents
:
|
20136615 - New insights on fetal ductal constriction: role of maternal ingestion of polyphenol-ric... 2888205 - Approaches to defining the relationship of maternal and developmental toxicity. 20211035 - Maternal dietary patterns in pregnancy and the association with small-for-gestational-a... 22374755 - Serotonergic effects on feeding, but not hypothalamo-pituitary-adrenal secretion, are a... 19900145 - Advanced twin abdominal pregnancy: diagnostic and therapeutic challenges. 11584485 - Risk factors for antepartum fetal death. |
Publication Detail:
|
Type: Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't Date: 2010-01-20 |
Journal Detail:
|
Title: BJOG : an international journal of obstetrics and gynaecology Volume: 117 ISSN: 1471-0528 ISO Abbreviation: BJOG Publication Date: 2010 Apr |
Date Detail:
|
Created Date: 2010-04-08 Completed Date: 2010-06-08 Revised Date: 2010-10-19 |
Medline Journal Info:
|
Nlm Unique ID: 100935741 Medline TA: BJOG Country: England |
Other Details:
|
Languages: eng Pagination: 575-84 Citation Subset: AIM; IM |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adiposity
/
physiology Adult Body Mass Index* Cesarean Section / statistics & numerical data Female Fetal Growth Retardation / etiology Humans Hyperglycemia / etiology* Obesity / complications* Pre-Eclampsia / etiology Pregnancy Pregnancy Complications* Pregnancy Outcome Prenatal Diagnosis / methods Young Adult |
| Grant Support | |
ID/Acronym/Agency:
|
M01-RR00048/RR/NCRR NIH HHS; M01-RR00080/RR/NCRR NIH HHS; R01-HD34242/HD/NICHD NIH HHS; R01-HD34243/HD/NICHD NIH HHS |
| Comments/Corrections | |
Comment In:
|
Evid Based Med. 2010 Oct;15(5):152-3
[PMID:
20667904
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: A phase II trial of neoadjuvant erlotinib in patients with muscle-invasive bladder cancer undergoing...
Next Document: A mutant telomerase defective in nuclear-cytoplasmic shuttling fails to immortalize cells and is ass...